Suppliers and packagers for moxidectin

moxidectin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mdgh	MOXIDECTIN	moxidectin	TABLET;ORAL	210867	NDA	Medicines Development for Global Health	71705-050-01	500 TABLET in 1 BOTTLE, PLASTIC (71705-050-01)	2019-12-02

Suppliers and packagers for moxidectin

Last updated: June 3, 2026

Moxidectin Suppliers: Who Manufactures Moxidectin API and Finished Dosage, and Where Does Supply Chain Risk Sit?

Moxidectin supply is split between (1) API producers (active ingredient) and (2) manufacturers of finished veterinary or pharmaceutical products that rely on those APIs. Public lists of “suppliers” vary by jurisdiction, dosage form (tablet, pour-on, injectable), and whether the product is veterinary (most moxidectin commercial supply) versus human-use investigational use.

Who supplies moxidectin API and finished products?

What counts as an “API supplier” for moxidectin

For moxidectin, “supplier” in procurement and licensing contexts typically means one of these:

• Manufacturer of moxidectin active pharmaceutical ingredient (API) or API intermediate chain for final API synthesis.
• Contract manufacturer that produces a finished dosage form from purchased moxidectin API.
• Distributor/reseller that sources from API producers and sells to formulators or regional product holders.

What is publicly available for moxidectin supply

Moxidectin is widely used in veterinary parasiticides (for example, heartworm and external parasites in animals), and the supplier universe often appears through:

• Approved product manufacturers and their contract manufacturing footprints.
• API vendor catalogs and trade listings that name moxidectin as an ingredient.
• Establishment and inspection records tied to API manufacturing sites (often not consistently mapped to a single named “supplier” in third-party databases).

Because moxidectin supply chains are product- and region-specific, the most stable supplier identification comes from the finished-product authorization package and the listed manufacturing sites, then tracing the API supply contract where disclosed.

Which companies make moxidectin veterinary products and who are their manufacturing partners?

How finished-product manufacturers map to “moxidectin suppliers”

Finished-product manufacturers who hold market authorization generally list:

• Product label/manufacturer or product owner (market authorization holder)
• Manufacturing sites for drug product (fill-finish, tablet compression, or solution preparation)
• Packaging sites

Those sites are the most actionable procurement points for “supply of moxidectin products,” while API sources require either:

• Disclosure through DMFs or supply chain statements, or
• Direct vendor sourcing (API procurement) paired to vendor qualification.

Common moxidectin dosage forms in supply

• Oral tablets or chewables (common in veterinary heartworm and parasitic indication products)
• Pour-on or spot-on topical formulations (external parasite control)
• Injectable formulations (where authorized for specific veterinary uses)

Each form typically draws on different excipient systems and manufacturing lines, even when the moxidectin API supplier is the same.

Is moxidectin available as a bulk API for generic or off-label formulation?

Procurement reality

Bulk API procurement for moxidectin is feasible in principle, but practical constraints usually include:

• Batch qualification demands (impurity profile, polymorph or isomer profile if relevant to vendor specification)
• Supply reliability and lead times
• Regulatory documentation availability (DMF reference, CoA standards, traceability)

What “API supplier” buyers usually require

• Full CoA for each lot, including assay and impurity panel
• Manufacturing site documentation for GMP compliance
• Specific stereochemical and impurity specs consistent with intended route/formulation
• Supply agreements that support repeat manufacturing schedules

How do I identify moxidectin API suppliers from regulatory filings?

DMFs and establishment listings

The most defensible supplier identification method is to:

• Use the drug substance authorization trail (DMF or equivalent in the relevant region)
• Cross-reference the drug product authorization’s manufacturing sites
• Link these to a likely API vendor or an API intermediate vendor

In many cases, finished-product authorization does not disclose the named API supplier, so filings identify manufacturing sites more reliably than brand-level API vendors.

What supply chain risks matter for moxidectin?

Risk categories that affect availability

• Single-site API dependence (risk of production interruption)
• Batch rejection risk (impurity or spec nonconformance)
• Transport and storage constraints (stability and temperature/light controls for moxidectin-containing intermediates and finished solutions)
• Time-to-qualify for a new API supplier (QA comparability and method validation requirements)

How to screen suppliers operationally

Procurement qualification typically checks:

• GMP compliance records for the API site
• History of supply continuity (ability to ship on cycle)
• Regulatory audit outcomes (warning letters, serious deviations)
• Analytical capability to support impurity methods and specification control

Which regions have the most reliable moxidectin supply?

Typical sourcing pattern

Moxidectin API sourcing is often concentrated in established chemical-manufacturing clusters serving veterinary parasiticide markets, with final product manufacturing distributed across authorization-holding regions.

From a buyer standpoint, the most reliable “supplier list” is usually:

1. The approved finished-product manufacturer(s) serving your market
2. The GMP manufacturing site(s) in that product authorization
3. The qualified API vendors that can provide full documentation aligned to your regulatory route

How does moxidectin supply differ from “generic” drug supply?

Veterinary parasiticide economics

Moxidectin is commonly distributed through veterinary product channels. Generic competition exists at the product level by authorization, but API supply may remain concentrated because:

• Synthesis is specialized
• Quality control specs are strict
• Documentation support for repeat lots is required

As a result, supplier switching is often slower than a simple change in finished-product packager.

Key Takeaways

• “Moxidectin suppliers” should be mapped into API producers versus finished-product manufacturers because the procurement decision changes accordingly.
• Finished-product manufacturing sites are the most concrete starting points; API supplier names often require regulatory-trail mapping through drug substance filings or DMFs.
• Supply chain risk centers on single-site API dependence, batch/spec conformance, and qualification time for new API vendors.
• For actionable sourcing, prioritize GMP site qualification and documentation readiness over vendor catalog names alone.

FAQs

1) What is the difference between moxidectin API suppliers and moxidectin product manufacturers?

API suppliers make the active ingredient; product manufacturers make the finished dosage form (tablet, pour-on, injectable) using that API under GMP.

2) Can I buy moxidectin bulk API for compounding or formulation?

Bulk procurement is possible but typically requires GMP-aligned documentation, CoA with impurity panels, and qualification for your intended dosage form and regulatory purpose.

3) How do I vet a new moxidectin API supplier?

Use GMP evidence, CoA consistency, validated analytical methods for impurities, and comparability testing against your target specification for the dosage form.

4) Which moxidectin dosage forms have the most complex sourcing?

Topical solutions and injectables often have more stringent stability, container-closure, and filling requirements than tablet formats.

5) Where do supply disruptions most often occur for moxidectin?

At API manufacturing sites or during batch release failures tied to impurity/spec deviations, plus downstream packaging or fill-finish constraints for the finished product.

References